CytomX Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021
July 29, 2021 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...
CytomX Therapeutics Announces Publication of First-in-Human Data for CX-2029 in Clinical Cancer Research
June 21, 2021 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...
CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference
May 27, 2021 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...
CytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
May 06, 2021 16:15 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...
CytomX Therapeutics to Announce First Quarter 2021 Financial Results on May 6, 2021
April 29, 2021 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...
CytomX Therapeutics Announces New Employment Inducement Grants
April 14, 2021 16:01 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of...
CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021
March 24, 2021 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of...
CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
February 24, 2021 16:15 ET
|
CytomX Therapeutics Inc.
-Broad advancement of clinical pipeline- -Three-arm Phase 2 study of praluzatamab ravtansine (CX-2009) launched in breast cancer- -Enrollment continues in Phase 2 expansion study of CX-2029 in four...
CytomX Therapeutics to Present at Upcoming March Virtual Investor Conferences
February 22, 2021 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of...
CytomX Therapeutics Announces New Employment Inducement Grant
February 19, 2021 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...